An interventional study of Pomegranate Fruit Extract and Pomegranate Fruit Extract in Sarcopenic Obesity, Sarcopenia and Obesity, sponsored by The Hong Kong Polytechnic University. Not yet recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.
Among the 83 studies in Sarcopenia with a site in China, this one is the 49th largest by planned enrollment of the 52 interventional ones that give a count, is one of 16 that started in 2026, is one of 42 with no phase, reaches primary completion later than 21 of the 51 other live ones, and was the 83rd registered.
1,334 studies on the registry are indexed under Sarcopenia; 417 are open to participants now.
Browse Sarcopenia studies →47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:
Shanghai Yueyang Integrated Medicine Hospital · Sites in China
Ages 60–90
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 60+
GuangZhou Cellgenes Biotechnology Co., Ltd. · Sites in China
Ages 50–85
Peking Union Medical College Hospital · Sites in China
Ages 18+
China Medical University, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 3
First in 2012; this study’s year is marked. 16 started in 2026.
This study's planned enrollment of 30 is below the median of 60 across 859 interventional studies indexed under Sarcopenia.
Median enrollment 110 across the 52 interventional studies, 868 across the 31 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 83 have an industry lead sponsor. The 10 most frequent:
The Hong Kong Polytechnic University is the lead sponsor of 685 studies on the registry; 262 are open to participants now.
The Hong Kong Polytechnic University has 5 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
14 of the studies in Sarcopenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07950150The Hong Kong Polytechnic UniversityPomegranate-Prebiotic Supplementation for Sarcopenic Obesity | 2026-12 |
| NCT07049731Weiwei MaImprovement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise | 2026-12 |
| NCT07724587Ningbo Medical Center Lihuili HospitalThe Effectiveness and Safety of Combined Research on Uremic Sarcopenia | 2026-12-01 |
| NCT07059871Zhejiang HospitalA Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. | 2026-12-30 |
| NCT07538674Shanghai Yueyang Integrated Medicine HospitalPeiyuan Guben Tongluo Ointment for Elderly Sarcopenia | 2027-03-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 83 studies in Sarcopenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenic obesity (SO) in older adults involves the co-occurrence of skeletal muscle decline and excessive body fat. This project investigates the gut-muscle axis, specifically how gut bacteria convert dietary polyphenols (such as ellagic acid found in pomegranates) into a muscle-protecting metabolite called Urolithin A (UA). This study is a randomized crossover pilot trial in 30 older adults with SO. It tests whether combining a pomegranate extract supplement with a prebiotic (Fructo-oligosaccharides, or FOS) increases the body's production of UA more effectively than pomegranate extract alone over a 7-day period.
Background and Rationale Sarcopenic obesity (SO) is a major public health challenge that significantly increases the risk of frailty, functional dependence, and metabolic comorbidities in aging populations. Current lifestyle and nutritional interventions often fail to address the underlying mitochondrial dysfunction and chronic low-grade inflammation central to the pathogenesis of SO. Recently, the gut-muscle axis has emerged as a therapeutic target. Urolithin A (UA) is a gut-derived microbial metabolite synthesized from dietary ellagitannins and ellagic acid (abundant in pomegranates) that activates mitophagy and improves mitochondrial health in skeletal muscle. However, UA synthesis is highly variable and depends on individual gut microbial composition, which is often compromised in older adults with obesity and sarcopenia (dysbiosis). Recent evidence suggests that prebiotics like Fructo-oligosaccharides (FOS) can promote the specific bacterial strains (Bifidobacterium and Enterococcus species) required for the two-step bioconversion of ellagic acid into UA.
This is a clinical pilot trial designed to test the feasibility and biological efficacy of a synergistic nutritional intervention. A total of 30 older adults diagnosed with SO will be enrolled in a randomized crossover trial. Each participant will undergo two 7-day intervention periods separated by a 14-day washout period.
Intervention A includes pomegranate extract alone (yielding 200 mg/day of ellagic acid). Intervention B includes pomegranate extract (yielding 200 mg/day of ellagic acid) combined with FOS prebiotic powder (5 g/day).
Because each participant serves as their own control, the crossover design eliminates the confounding effect of individual variability in baseline gut microbiome composition. The primary outcome is the within-participant difference in 24-hour urinary UA excretion (normalized to creatinine) between the combined intervention and the single-component intervention. Secondary outcomes include changes in fecal urolithin concentrations and shifts in gut microbiota composition assessed via 16S rRNA sequencing. Findings will inform the design of a fully powered randomized controlled trial testing this cost-effective synbiotic strategy for managing SO.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract alone.
Dietary Supplement: Pomegranate Fruit Extract
Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract in combination with FOS prebiotic powder.
Dietary Supplement: Pomegranate Fruit Extract · Dietary Supplement: Fructo-oligosaccharides (FOS) Prebiotic
Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days.
Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days.
Two teaspoons (5 g/day) daily of Source Naturals FOS Powder. Provided as pre-measured daily sachets of bulk powder to be mixed with water, juice, or food and consumed orally for 7 consecutive days.
24-Hour Urinary Urolithin A Excretion
Within-participant difference in 24-hour total urinary urolithin A excretion normalized to urinary creatinine between the Pomegranate Extract + FOS intervention period and the Pomegranate Extract Alone intervention period. Measured via UHPLC-MS/MS.
Time frame: Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).
24-Hour Total Urinary Urolithins Profile
Total excretion of urolithin metabolites and intermediates (including urolithin B and urolithin C) measured in 24-hour batch urine samples using UHPLC-MS/MS.
Time frame: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
Gut Microbiota Composition
Relative abundance and community structure of target gut bacteria (including Bifidobacterium species and urolithin-converting taxa) determined by 16S rRNA gene sequencing (V3-V4 hypervariable region) on an Illumina MiSeq platform.
Time frame: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
Fecal Urolithin Concentrations
Concentrations of urolithin A, urolithin B, and urolithin C in self-collected homogenized fecal samples, extracted and quantified via UHPLC-MS/MS.
Time frame: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 1 month is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hong Kong Polytechnic University →